Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Fiche du document
2015
- doi: 10.1186/s12876-015-0259-5
- issn: 1471-230X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12876-015-0259-5
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/25887762
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1471-230X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_2416C6CBDE272
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
HCV (Hepatitis C virus) Ribovirin Virazole Ribofuranosyltriazolecarboxamide Parenterally-transmitted non-A, non-B hepatitis Non-A, non-B hepatitis, Parenterally-transmitted Hepatitis, Non-A, non-BCiter ce document
J. Vionnet et al., « Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report. », Serveur académique Lausannois, ID : 10.1186/s12876-015-0259-5
Métriques
Partage / Export
Résumé
BACKGROUND: Recurrent hepatitis C virus infection after liver transplantation is associated with reduced graft and patient survival. Re-transplantation for graft failure due to recurrent hepatitis C is controversial and not performed in all centers. CASE PRESENTATION: We describe a 54-year-old patient with hepatitis C virus genotype 1b infection and a null response to pegylated interferon-α and ribavirin who developed decompensated graft cirrhosis 6 years after a first liver transplantation. Treatment with sofosbuvir and ribavirin allowed for rapid negativation of serum HCV RNA and was well tolerated despite advanced liver and moderate renal dysfunction. Therapeutic drug monitoring did not reveal any clinically significant drug-drug interactions. Despite virological response, the patient remained severely decompensated and re-transplantation was performed after 46 days of undetectable serum HCV RNA. The patient is doing well 12 months after his second liver transplantation and remains free of hepatitis C virus. CONCLUSIONS: The use of directly acting antivirals may allow for successful liver re-transplantation for recipients who remain decompensated despite virological response and is likely to improve the outcome of liver re-transplantation for end-stage recurrent hepatitis C.